More money is going to be coming from joint ventures with big pharma. The use of a proven technology is going to add to the list of companies looking for a target. New ones are coming up all of the time and seem to have efficacy in areas beyond oncology.
The earnings will continue to grow and allow for nondilutive investments with drugs that SGEN chooses to develop or partner with. Some milestones should be coming and added revenue from the Canadians. Time frame to add more patients and introduction into the Canadian market should start shortly and accretive to earnings.
Only just beginning to be recognized but the growth will continue.
This this could be good? Over the last year and a half it's been buy the rumor-sell the news. This is at least different.
I still think they could book some of the current milestones as income this quarter and show a profit. The truth is they ARE profitable for 2012 as measured by cash flow. I hope they find a way to communicate that.
We will either see $25 or $35 in the next week. I'm hoping for the buying opportunity but I think it will go higher instead. Today may be the day to buy?
We will have to see if they are still conservative on the 2013 revenue guidance.